Author

William Sandborn 1

1 University of California San Diego

EARLY RESPONSES IN PATIENT-REPORTED OUTCOMES ARE PREDICTORS FOR MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH GOLIMUMAB- RESULTS FROM PURSUIT SC INDUCTION

Walter Reinisch, Brian G. Feagan, Colleen W. Marano, Richard S Strauss, C. Han, Jewel Johanns, Hongjie Zhang, Peter R. Gibson, John Collins, Paul Rutgeerts, William Sandborn, Jean-Frederic Colombel, Brian G. Feagan, Gunnar Jarnerot

Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Julian Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Kristina Kligys, Kori Wallace, Xiaomei Liao, Wan-Ju Lee, Markus F. Neurath

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFECT OF MIRIKIZUMAB ON INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF PATIENTS WITH CROHN'S DISEASE

Geert R. D'Haens, Stefan Schreiber, Edouard Louis, Bruce E. Sands, Elisa Gomez Valderas, Debra Miller, Noah Agada, April Naegeli, Paul Pollack, Jochen Schmitz, Janneke van der Woude, Jaroslaw Kierkuś, William Sandborn

EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet, Maria T. Abreu, Silvio Danese, Colleen W. Marano, Yiying Zhou, Hongyan Zhang, Rupert W Leong, David Rowbotham, Remo Panaccione, William Sandborn

EFFECTS OF IMMUNOMODULATORS ON THE PHARMACOKINETICS AND EFFICACY OF GOLIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM PHASE 2/3 PURSUIT –SC INDUCTION AND MAINTENANCE STUDIES

Zhi-jie Xu, Colleen W. Marano, Richard S Strauss, Hongjie Zhang, H M Davis, Walter Reinisch, Brian G. Feagan, Paul Rutgeerts, Omoniyi J. Adedokun, Jean-Frederic Colombel, William Sandborn

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris, William Sandborn, Brian G. Feagan, Stephen B Hanauer, Severine Vermeire, Subrata Ghosh, Wenzhong Liu, Douglas C. Wolf, Geert D’Haens

EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL

Geert R. D'Haens, William Sandborn, Wenwen Zhang, Krisztina Kisfalvi, Song Wang, Severine Vermeire

Effects of Ustekinumab Maintenance Therapy on Endoscopic Improvement and Histologic Improvement in the UNIFI Phase 3 Study in Ulcerative Colitis

Katherine Li, Joshua R. Friedman, Colleen W. Marano, Hongyan Zhang, Feifei Yang, William Sandborn, Bruce E. Sands, Brian G. Feagan, Laurent Peyrin-Biroulet, Gert De Hertogh

EFFICACY AND IMPROVED HEALTH-RELATED QUALITY OF LIFE AFTER 52-WEEKS OF MIRIKIZUMAB TREATMENT IN PATIENTS WITH ULCERATIVE COLITIS: AN UPDATE FROM A RANDOMISED, DOUBLE-BLIND, CONTROLLED, PHASE 2 STUDY

Marc Ferrante, William Sandborn, Bal R Bandhari, Geert D’Haens, Brian G. Feagan, Michael Durante, Vipin Arora, Jay Tuttle, April Naegeli

Item 41 - 50 / 206
1
...
2 3 4
5
6 7 8
...
21